Sedative and Hypnotics: Classification, Mechanism, Therapeutic Uses, Adverse Effects, and Contraindications
Sedative and hypnotic drugs are primarily used to induce relaxation, reduce anxiety, and promote sleep. They are classified into benzodiazepines, barbiturates, non-benzodiazepine hypnotics, and other sedatives.
Classification
- Benzodiazepines (e.g., diazepam, lorazepam)
- Barbiturates (e.g., phenobarbital, secobarbital)
- Non-benzodiazepine hypnotics (e.g., zolpidem, eszopiclone)
- Other sedatives (e.g., antihistamines like diphenhydramine)
Mechanism of Action
- Benzodiazepines: Enhance GABAergic activity at the GABA-A receptor, increasing chloride influx, leading to neuronal inhibition.
- Barbiturates: Enhance GABAergic activity and directly open chloride channels in GABA-A receptors, causing CNS depression.
- Non-benzodiazepine hypnotics: Selectively act on the GABA-A receptor alpha-1 subunit, promoting sleep with fewer side effects.
Therapeutic Uses
- Benzodiazepines: Anxiety, insomnia, seizures, muscle relaxation, alcohol withdrawal
- Barbiturates: Seizures, general anesthesia, insomnia
- Non-benzodiazepine hypnotics: Short-term treatment of insomnia
Adverse Effects
- Benzodiazepines: Drowsiness, memory impairment, dependence, respiratory depression
- Barbiturates: Sedation, respiratory depression, dependence, overdose risk
- Non-benzodiazepine hypnotics: Drowsiness, dizziness, tolerance, sleepwalking
Contraindications
- Benzodiazepines: Acute narrow-angle glaucoma, severe respiratory disorders, pregnancy
- Barbiturates: Hepatic impairment, respiratory depression, pregnancy
- Non-benzodiazepine hypnotics: Sleep apnea, alcohol intoxication
Benzodiazepines vs. Barbiturates
Benzodiazepines are preferred over barbiturates due to their wider therapeutic index, lower risk of overdose, fewer drug interactions, and a lower risk of addiction.
Newer Non-Benzodiazepine Hypnotics
Newer non-benzodiazepine hypnotics, such as zolpidem, eszopiclone, and zaleplon, are preferred for insomnia due to their specific action on the GABA-A receptor, reducing side effects and risk of dependence.